How to Recognize and Overcome Pulmonary Hypertension Crisis During Patent Ductus Arteriosus Closure by Device in Adult

Authors

  • Lukitasari Ayu Galuh Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
  • Heny Martini Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.

DOI:

https://doi.org/10.21776/ub/hsj.2024.005.02.11

Keywords:

Case Report, Pulmonary Hypertension Crisis, Patent Ductus Arteriosus, Congenital Heart Disease Intervention

Abstract

BACKGROUND: Managing a patent ductus arteriosus (PDA) with severe pulmonary hypertension (PH) is challenging since closing the PDA can result in reduced cardiac output and right ventricular (RV) failure. The latest guideline for Adult Congenital Heart Disease (ACHD) stated it is harmful to close the defect in patients with pulmonary vascular resistance (PVR) ≤5 WU and flow ratio (FR) <1.5.  

CASE ILLUSTRATION: A 37-year-old female was referred with cough, fever, low saturation, and murmur findings. After serial examination, she was diagnosed with large PDA and severe PH her peripheral saturation (SaO2) was 88%-89% and non-responder to acute vasoreactivity test. After a year of PH therapy, vasoreactivity showed a response to the vasoreactivity test and improved on clinical presentation with SaO2 91%-92%. Patient fell in to PH crisis condition during the procedure of device closure, prostacyclin analogue intravenous (IV) and phosphodiesterase inhibitors inhalation was administered, and the procedure was carried on. The device was successfully implanted, and the patient had SaO2 97% in all four extremities before discharge.

CONCLUSION: With established PH therapy, PDA with severe PH can underwent PDA closure by device with satisfying outcome.

 

References

Chiu SN, Lu CW, Lin MT, Chen CA, Wu MH, Wang JK. Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease. J Am Heart Assoc. 2022;11(7). doi:10.1161/JAHA.121.022596

Galiè N, McLaughlin V V., Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. In: European Respiratory Journal. Vol 53. European Respiratory Society; 2019. doi:10.1183/13993003.02148-2018

Zhou Z, Gu Y, Zheng H, et al. Interventional Occlusion of Large Patent Ductus Arteriosus in Adults with Severe Pulmonary Hypertension. J Clin Med. 2023;12(1). doi:10.3390/jcm12010354

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237

Baumgartner H, de Backer J, Babu-Narayan S V., et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. doi:10.1093/eurheartj/ehaa554

Niu MC, Mallory GB, Justino H, Ruiz FE, Petit CJ. Treatment of severe pulmonary hypertension in the setting of the large patent ductus arteriosus. Pediatrics. 2013;131(5). doi:10.1542/peds.2011-1417

Brunner N, de Jesus Perez VA, Richter A, et al. Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery. Pulm Circ. 2014;4(1):10-24. doi:10.1086/674885

Majure DT, Greco T, Greco M, et al. Meta-analysis of randomized trials of effect of milrinone on mortality in cardiac surgery: An update. J Cardiothorac Vasc Anesth. 2013;27(2):220-229. doi:10.1053/j.jvca.2012.08.005

Ovaert C, Thijs D, Dewoif,’ D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 1009;9:331-339. doi:10.1O17/S1O47951109990023

Downloads

Published

2024-04-28

Issue

Vol. 5 No. 2 (2024): Challenges in the Management of Congenital Heart and Structural Heart Diseases

Section

Case Report

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).